Literature DB >> 18446058

T-CAM, a fastatin-FIII 9-10 fusion protein, potently enhances anti-angiogenic and anti-tumor activity via alphavbeta3 and alpha5beta1 integrins.

Ju-Ock Nam1, Mi-Yeon Jung, Narendra Thapa, Byung-Heon Lee, Rang-Woon Park, In-San Kim.   

Abstract

We made fusion protein of fastatin and FIII 9-10, termed tetra-cell adhesion molecule (T-CAM) that can interact simultaneously with alphavbeta3 and alpha5beta1 integrins, both playing important roles in tumor angiogenesis. T-CAM can serve as a cell adhesion substrate mediating adhesion and migration of endothelial cells in alphavbeta3 and alpha5beta1 integrin-dependent manner. T-CAM showed pronounced anti-angiogenic activities such as inhibition of endothelial cell tube formation, endothelial cell proliferation, and induction of endothelial cell apoptosis. T-CAM also inhibited angiogenesis and tumor growth in mouse xenograft model. The anti-angiogenic and anti-tumoral activity of molecule like fastatin could be improved by fusing it with integrin-recognizing cell adhesion domain from other distinct proteins. The strategy of combining two distinct anti-angiogenic molecules or cell adhesion domains could facilitate designing improved anticancer agent of therapeutic value.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446058      PMCID: PMC2679300          DOI: 10.3858/emm.2008.40.2.196

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  25 in total

1.  Inhibition of endothelial cell survival and angiogenesis by protein kinase A.

Authors:  Semi Kim; Manjiri Bakre; Hong Yin; Judith A Varner
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 2.  Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.

Authors:  Gian Carlo Alghisi; Curzio Rüegg
Journal:  Endothelium       Date:  2006 Mar-Apr

3.  Recombinant tetra-cell adhesion motifs supports adhesion, migration and proliferation of keratinocytes/fibroblasts, and promotes wound healing.

Authors:  Mi Yeon Jung; Narendra Thapa; Jung Eun Kim; Jung Duk Yang; Byung Chae Cho; In San Kim
Journal:  Exp Mol Med       Date:  2007-10-31       Impact factor: 8.718

4.  Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth.

Authors:  G D Kamphaus; P C Colorado; D J Panka; H Hopfer; R Ramchandran; A Torre; Y Maeshima; J W Mier; V P Sukhatme; R Kalluri
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

5.  A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis.

Authors:  M Yi; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

6.  Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3.

Authors:  J E Kim; S J Kim; B H Lee; R W Park; K S Kim; I S Kim
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

7.  betaig-h3 triggers signaling pathways mediating adhesion and migration of vascular smooth muscle cells through alphavbeta5 integrin.

Authors:  Byung Heon Lee; Jong Sup Bae; Rang Woon Park; Jung Eun Kim; Jae Yong Park; In San Kim
Journal:  Exp Mol Med       Date:  2006-04-30       Impact factor: 8.718

8.  Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin.

Authors:  S Kim; K Bell; S A Mousa; J A Varner
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 9.  Role of integrins in cancer: survey of expression patterns.

Authors:  G J Mizejewski
Journal:  Proc Soc Exp Biol Med       Date:  1999-11

10.  Defining fibronectin's cell adhesion synergy site by site-directed mutagenesis.

Authors:  S D Redick; D L Settles; G Briscoe; H P Erickson
Journal:  J Cell Biol       Date:  2000-04-17       Impact factor: 10.539

View more
  1 in total

1.  TGFBI Expression Predicts the Survival of Patients With Oropharyngeal Squamous Cell Carcinoma.

Authors:  Ha-Jeong Kim; Dongbin Ahn; Tae-In Park; Ji Yun Jeong
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.